Who Are the Core Customers in Treace Medical Concepts Company's Target Market?

Treace Medical Concepts target customers are primarily foot and ankle surgeons – orthopedic surgeons and podiatric surgeons – because they make clinical decisions and perform Lapiplasty procedures; as of early 2026 over 3,200 active surgeons are trained on Treace proprietary systems, driving device adoption and referral patterns.

Bunion patients form the secondary target: roughly 1.1 million U.S. patients seek bunion surgery annually, with Treace focusing on moderate-to-severe cases who failed conservative care and want a low-recurrence solution; care settings include ambulatory surgery centers and hospital ORs and podiatry clinics.

Treace serves a mixed customer base: institutional purchasers (hospital purchasing managers, ASCs) and clinicians (surgeons) as primary buyers, plus individual patients who select procedures; purchasing decisions hinge on clinical outcomes, surgeon preference, and insurance coverage for Lapiplasty.

Foot and ankle surgeons are most important by revenue and strategic relevance: trained surgeon count correlates with procedure volume and device sales; hospital and ASC purchasing managers determine capital and implant procurement, shaping scalable penetration.

Ambulatory surgery centers (ASCs) and outpatient departments drive the strongest demand because elective foot and ankle procedures moved outpatient for cost-efficiency and throughput; ASCs accounted for an estimated ~60% of procedural volume for Lapiplasty-type interventions in 2025 in key US metros.

Geographically, penetration is highest in affluent metropolitan areas (California, Texas metros, Northeast suburbs) where bunion patients and foot and ankle surgeons show higher elective spending; podiatry clinics and specialty orthopedic centers form meaningful secondary demand pockets.

Treace Medical Concepts is strongest where foot and ankle surgeons adopt the Lapiplasty system and hospital purchasing decision makers at ASCs favor value-per-procedure; by FY2025 the revision and ancillary-procedure mix contributed a measurable share to revenue, supporting broader OR and ASC adoption.

Demand accelerated in the revision surgery market through Q1 2026 as patients with failed traditional bunion repairs seek Lapiplasty for permanent correction; expansion into hammertoe and midfoot fusion increased ancillary procedure revenue, together accounting for a growing portion of total procedural revenue by early 2026. Read the Competitive Landscape of Treace Medical Concepts Company for more context: Competitive Landscape of Treace Medical Concepts Company

Treace expands by using its established sales force to cross-sell Adductoplasty and hammertoe systems to existing foot and ankle surgeons and orthopedic surgeons, and by targeting ambulatory surgery centers and podiatry clinics to reach bunion patients and new referral streams.

Retention rests on the stickiness of Lapiplasty instrumentation, mandatory specialized training for surgeons, high switching costs, and referral flow from direct-to-consumer campaigns that funnel patients to trained providers.

Repeat demand grows as surgeons adopt multi-procedure suites (bunion, hammertoe, Adductoplasty). With gross margins above 80 percent in 2025, Treace reinvests in patient marketing and Center of Excellence networks that deepen surgeon-patient relationships and increase average revenue per case.

The top lever is the high-touch surgeon education model plus product-line expansion: cross-selling raised average case revenue in 2025 while the trained surgeon base is projected to rise 18 percent to 22 percent annually through 2026, pushing Treace toward positive cash flow and deeper penetration into high-volume podiatric markets.